SITE006-0258

SITE006 (GBR) › SITE006-0258

SITE006-0258

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-07-05

enrolled

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 53); relationship: NOT RELATED; serious criteria: hospitalization

severe serious under_review

Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-02-12 (study day 36); relationship: not assessed

moderate assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 4); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.